Next Article in Journal
Feeding Approach to Optimizing Nutrition in Infants with Congenital Heart Disease
Previous Article in Journal
Ontogeny of Fetal Cardiometabolic Pathways: The Potential Role of Cortisol and Thyroid Hormones in Driving the Transition from Preterm to Near-Term Heart Development in Sheep
Previous Article in Special Issue
Computed Tomography Coronary Angiography Is Feasible and Reliable for Proximal Coronary Segment Interpretation in Patients with Elevated Body Mass Index
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCDD
Volume 12
Issue 2
10.3390/jcdd12020037
jcdd-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

High-Risk Plaque Characteristics in Patients with Suspected Stable Coronary Artery Disease and Impaired Glucose Tolerance: A Coronary Computed Tomography Angiography Study

by
Thomas Rueskov Andersen
1,2,
Katrine Schultz Overgaard
1,2,
Laurits Juhl Heinsen
1,2,
Roda Abdulkadir Mohamed
1,2,
Freja Sønder Madsen
1,
Helle Precht
1,3,4,5,6,
Jess Lambrechtsen
1,2,
Søren Auscher
1,2 and
Kenneth Egstrup
1,2,*
1
Cardiovascular Research Unit, Odense University Hospital Svendborg, 5700 Svendborg, Denmark
2
Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, 5230 Odense, Denmark
3
Health Sciences Research Centre, UCL University College, 5230 Odense, Denmark
4
Department of Radiology, Lillebaelt Hospital, University Hospitals of Southern Denmark, 6000 Kolding, Denmark
5
Institute of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark
6
Discipline of Medical Imaging and Radiation Therapy, University College Cork, T12 K8AF Cork, Ireland
*
Author to whom correspondence should be addressed.
J. Cardiovasc. Dev. Dis. 2025, 12(2), 37; https://doi.org/10.3390/jcdd12020037
Submission received: 9 December 2024 / Revised: 9 January 2025 / Accepted: 15 January 2025 / Published: 22 January 2025
(This article belongs to the Special Issue Coronary Artery Disease: Risk Stratification and Optimization of Intervention Strategies)
Browse Figures
Versions Notes

Abstract

Impaired glucose tolerance (IGT), a prediabetic state, is a known risk factor for coronary artery disease (CAD). Low-attenuation plaque (LAP) lesions are associated with a high risk of coronary events. We aimed to evaluate high-risk plaque characteristics in LAP lesions between patients with IGT and normal glucose tolerance (NGT) in patients suspected for stable CAD. Coronary computed tomography angiography (CCTA) identified LAP lesions and assessed plaque volumes, burdens, and high-risk plaque features. Glycemic tolerance was stratified using oral glucose tolerance tests. Among 148 patients, 202 LAP lesions were identified, with 93 patients classified as NGT and 55 as IGT. Patients with IGT had a significantly higher prevalence of LAP lesions compared with NGT (p = 0.007). LAP volume was higher in IGT (16.46 ± 12.52 mm3) compared with NGT (12.66 ± 9.72 mm3, p = 0.01), but this association did not persist in multivariate analysis. The LAP burden was greater in IGT (10.79 ± 6.84%) than NGT (8.62 ± 5.93%, p = 0.02), and the napkin-ring sign was more frequent in IGT (12%) versus NGT (5%, p = 0.02); these associations remained significant in multivariate analysis. Patients with IGT had a higher LAP burden and higher frequency of napkin-ring signs. These findings may help explain the common occurrence of prediabetes in patients with acute myocardial infarction.

1. Introduction

Impaired glucose tolerance (IGT), an intermediate state between normal glucose metabolism and type 2 diabetes mellitus (T2DM), is a well-established risk factor for coronary artery disease (CAD) [1]. As part of the broader category of prediabetes, which also includes impaired fasting glucose (IFG), IGT has shown a particularly strong association with adverse CAD outcomes [2]. While prediabetes can be assessed using glycated hemoglobinA1c (HbA1c) levels, 2-h plasma glucose (2-hPG) levels ≥ 9 mmol/L are superior for predicting CAD progression [3]. This emphasizes the importance of using the oral glucose tolerance test (OGTT) as a primary screening tool to identify patients at elevated risk [3,4].
High-risk plaque characteristics, which are crucial determinants of cardiovascular (CV) outcomes, can be assessed using coronary computed tomography angiography (CCTA), a simple and non-invasive method. Understanding the relationship between IGT and plaque vulnerability is essential for effective risk stratification [5,6,7]. Low-attenuation plaques (LAPs), typically defined by Hounsfield Units (HUs) less than 30, are indicative of lipid-rich necrotic cores within atherosclerotic plaque [8]. Patients with acute coronary syndrome (ACS) often exhibit LAP lesions, which are associated with an increased risk of future CV events [9,10,11]. Additionally, patients who exhibit high-risk plaque (HRP) features, such as spotty calcification (SC), positive remodeling index (RI), and the napkin-ring sign (NRS), are at an increased risk of adverse CV outcomes [12].
Recent evidence from optical coherence tomography (OCT) studies has demonstrated that coronary plaques in patients with IGT exhibit a greater lipid core size and thinner fibrous caps, suggesting increased vulnerability similar to that observed in patients with T2DM [5,13]. Despite these findings, a significant knowledge gap remains in understanding how IGT contributes to high-risk plaque characteristics measured using CCTA.
In this observational study of patients with coronary low-attenuation plaque lesions, we compared the high-risk plaque characteristics, comprising plaque volumes, burdens, and high-risk plaque features in patients with normal and impaired glucose tolerance.

2. Materials and Methods

2.1. Study Design

This observational, prospective, single-center study included a blinded comparison between glycemic tolerance and coronary high-risk plaque characteristics. The study was conducted at the Outpatient Clinic of Cardiology and the Department of Cardiovascular Research at Odense University Hospital, Svendborg. We enrolled patients referred for CCTA due to suspected stable CAD between February 2018 and June 2020. All participants provided written informed consent, and the study received approval from the Regional Scientific Ethics Committee for Southern Denmark (project ID: S-20170094) and the Danish Data Protection Agency (project ID: 2012-58-0018).

2.2. Study Population

Patients were invited to participate during their CCTA visit and were subsequently scheduled for a consultation, during which written consent was obtained, medical history reviewed, and blood samples collected. The mean interval between CCTA and blood sampling was 29 days. Inclusion criteria were age ≥ 18 years, capacity to provide informed consent, and suspicion of stable CAD. Exclusion criteria included conditions unsuitable for contrast-enhanced CCTA, such as body mass index (BMI) > 40, irregular or fast heart rhythms incompatible with CCTA, reduced kidney function with an estimated glomerular filtration rate (eGFR) < 45 mL/min, and known contrast allergy.
A total of 586 consecutive patients with suspected CAD were initially enrolled (Figure 1). Patients with non-diagnostic CCTA scans were excluded (n = 61), and those scanned with low tube voltage were excluded for comparability reasons, as shown by Takagi et al. [14]. Next, glucose tolerance was evaluated and those with a T2DM diagnosis were excluded. For transparency, the characteristics and plaque data of T2DM patients, alongside those of NGT and IGT patients, have been included in the supplemental material (Tables S1 and S2). To ensure the exclusion of potentially undiagnosed T2DM, individuals with fasting plasma glucose (FPG) levels > 7.0 mmol/L or 2-h glucose values ≥ 11.1 mmol/L were excluded. Additionally, patients with IFG were excluded because of their high degree of similarity to those with normal glucose tolerance (NGT). This resulted in 312 patients, including 220 with NGT and 92 with IGT. Figure 1 illustrates the process of the study sample selection. Lesions with LAP were present in 93 of the 220 patients with NGT and 55 of the 92 patients with IGT, while those without a LAP lesion were excluded (n = 164).

2.3. Clinical and Biochemical Assessments

A questionnaire was used to evaluate CV risk factors, encompassing age, height, weight, smoking status, history of CAD, medical history, and medication use. Blood samples were obtained and assessed for various biomarkers, including HbA1c, FPG, 120 min plasma glucose, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, eGFR, creatinine, and C-reactive protein (CRP). HbA1c was categorized as pre-diabetic using the threshold of 39–47 mmol/mol from the American Diabetes Association (ADA) [15].

2.4. Glucose Tolerance Testing and Stratification

OGTT was performed after CCTA in patients without known T2DM. Patients were instructed to fast for 8 h before the OGTT. FPG was measured before 75 g of glucose was ingested over five minutes. After 120 min, plasma glucose was measured, and patients were stratified according to ADA definitions of glycemic status [15].
Patients were stratified into the following groups based on their OGTT results: NGT and IGT.

2.5. CCTA Acquisition

CCTA images were obtained using a standardized protocol on a 256-detector system (GE-revolution APEX CT, GE Healthcare, Waukesha, WI, USA). We also conducted an unenhanced scan to assess coronary artery calcium. Ivabradine 7.5 mg tablets were administered, one tablet the night before the scan and one tablet in the morning on scanning day to improve image quality. If necessary, intravenous beta-blockers were administered on the day of the scan. ECG-gated prospective acquisition in the 75% R-R interval, with additional padding of 45 ms to allow for additional construction, was used to obtain images. A total of 60 mL of iodine contrast (Visiplaque 320 mg iodine/mL) was injected at a rate of 5 mL/s, and the scan was timed when maximum attenuation was detected in the descending aorta. Tube voltage was adjusted based on the patient’s body size; patients scanned at 100–120 kV were included. The gantry rotation time was 280 ms with a 16 cm axial coverage. The slice thickness and interval for reconstruction were 0.625 mm, and 40% adaptive statistical iterative reconstruction was standardized. The highest-quality images were selected from the available phases and used for reconstruction and final analysis using dedicated software.

2.6. Quantitative CCTA Analysis

Quantitative CCTA analysis was performed using the semiautomatic, validated software (Qangio CT Research Edition 3.2.0.13, Medis, Leiden, The Netherlands) [16]. All images were blinded to the observer, TRA. The American Heart Association 17-segment model was used as a guideline for plaque localization. The coronary artery tree was automatically extracted, and centerlines were placed using the software. Cross-sectional and longitudinal images of the lumen and vessel wall were automatically created, with careful manual adjustments when necessary. Segments with insufficient quality, with a lumen of less than 1.5 mm, or with low levels of contrast were excluded. Patients were excluded if they had less than two vessels of adequate quality or with severe artifacts that compromised image quality (n = 61) (Figure 1).

High-Risk Plaque Characteristics

All vessels were examined for visible plaques and further evaluated using the semi-automatic software. Only lesions containing a minimum volume of LAP > 1 mm3 were evaluated [8]. The following high-risk plaque characteristics were extracted automatically per patient: total atheroma volume (TAV), vessel length, volumes of calcified plaque, non-calcified plaque, low-attenuation plaque, and lumen. Tissue volumes were extracted based on Hounsfield Unit (HU) values using a dynamic algorithm, converting HU thresholds into volumes according to luminal contrast densities [17]. The plaque burdens were calculated post-data extraction: percent plaque volume (PPV) per individual plaque component [(total calcified, non-calcified, and low attenuation plaque volume/total plaque volume) × 100%]. The coronary artery calcium score (CACS) was calculated using the Agatston method on non-contrast CCTA images [18]. HRP features, including NRS, RI, and SC, were evaluated for each LAP lesion identified (Figure 2). The napkin-ring sign was defined by a central area of low attenuation inside a semicircular area of higher attenuation (Figure 2A). Spotty calcifications were defined as small calcifications of <3 mm in any direction (Figure 2B). Positive remodeling index was calculated as the ratio of lesion plaque area to proximal reference area (Figure 2C) [19].

2.7. Statistical Analysis

All statistical analysis was performed using STATA IC 18 (StataCorp. 2023. College Station, TX, USA) and RStudio (RStudio Team, 2023 with R v. 4.3.2). Baseline characteristics are presented as means with standard deviations for continuous variables, and categorical variables are presented as totals and percentages of the total number per group. Patient and plaque level data were tested for normal distribution prior to analysis. Non-normally distributed variables are presented as medians and inter-quartile ranges. Student’s t-test was used to assess the difference in means of continuous variables between the two stratified groups (NGT and IGT). When appropriate, categorical parameters were described using the Chi-squared or Fisher’s test. The association between NGT and IGT groups with overall plaque burden and individual plaque components was tested using univariate and multivariate linear regression. HRP features were tested with univariate and multivariate logistic regression. All baseline characteristics with a p-value < 0.05 were tested using the Wald Test to determine whether they should be included in the final regression model.

3. Results

3.1. Clinical Characteristics

The initial cohort included 312 patients, with 220 classified as NGT and 92 as IGT (Figure 1). LAP lesions were present in 42% of the NGT group and a significantly higher prevalence of 60% was found in the IGT group (p = 0.007) (Figure 3). Patients without LAP lesions were excluded (n = 164), leaving 148 patients with 202 lesions for further analysis (NGT = 93, IGT = 55). Table 1 shows the patient characteristics. Patients with NGT were significantly older than those with IGT (64.7 vs. 61 years, p = 0.02). Male sex, BMI, and smoking history were similar in the two groups. Lipid profiles were largely comparable, likely due to a greater use of statins in the IGT group compared with NGT, with the exception of HDL, which was higher in the NGT group. CRP and triglyceride levels were significantly elevated in the IGT group.

3.2. CCTA Findings

Lesion length and TAV were similar in patients with NGT and IGT (Table 2). No differences were found in volumes and burdens of non-calcified and calcified plaques. A significantly higher volume and burden of LAP were found in patients with IGT compared with NGT (p = 0.01 and p = 0.02) (Figure 4). The HRP features RI and SC were numerically more prevalent in the IGT group but were not statistically significant. Patients with IGT exhibited a significantly higher frequency of NRS compared with NGT (12% vs. 5%, p = 0.02). The presence of two or more HRP features was more common in the IGT group but did not reach statistical significance.

3.3. Univariate and Multivariate Analysis

Table 3 presents a comparison of high-risk plaque characteristics. The univariate analysis demonstrated that the IGT group had significantly higher LAP volume and burden compared with the NGT group, this was also observed for the HRP feature NRS (all p = 0.02). In the multivariate model, the possible confounders (age, male sex, BMI, CRP, LDL, statin use, and smoking) were included. After adjusting for confounders, LAP burden remained significantly associated with IGT (β = 0.3, p = 0.03) and NRS remained significant in the multivariate analysis (odds ratio (OR) = 2.7, p = 0.02).

4. Discussion

This observational study aimed to compare the high-risk plaque characteristics in low-attenuation plaque lesions between patients with normal and impaired glucose tolerance. Our findings indicate that (1) the burden of low-attenuation plaque was significantly higher in IGT patients compared with NGT and (2) the napkin-ring sign was more frequent in IGT than NGT, while positive remodeling and spotty calcifications showed no significant differences. These results suggest that IGT may be associated with a more vulnerable plaque characteristic.

4.1. Prediabetes in a Clinical Context

Prediabetes is consistently recognized as a significant predictor of future CV events, with one study even suggesting it may pose a greater CV risk than well-managed T2DM [16,20]. Despite this elevated risk, no dedicated guidelines or therapeutic strategies currently target prediabetes for CV risk reduction. The 2023 ESC Guidelines [21] on the management of CV disease in patients with diabetes notably excluded prediabetes, focusing solely on manifest diabetes. This shift reflects an ongoing debate, as noted by Marx et al. [22], with some viewing prediabetes as a distinct clinical entity, while others attribute its risk to associated metabolic factors.
Our findings contribute to this debate, showing that among patients with LAP lesions, IGT was associated with a more vulnerable plaque characteristic compared with NGT. We found that patients with IGT exhibited a significantly higher burden of LAP, along with a greater prevalence of NRS. Importantly, these results persisted after adjusting for confounders, suggesting that IGT may play an independent role in influencing plaque vulnerability. However, the potential contribution of unmeasured risk factors cannot be excluded.

4.2. IGT vs. IFG: Different Paths to CVD?

The DECODE study [23] further highlighted the stronger CV risk associated with IGT compared with IFG. This distinction may be reflected in the differences in pathophysiology. Elevated FPG primarily indicates hepatic dysfunction in glucose regulation. In contrast, elevated 2-hPG reflects postprandial glucose dysregulation caused by decreased pancreatic insulin secretion and increased insulin resistance in peripheral tissues [22]. These mechanistic differences likely explain the stronger association of IGT with CV risk and underscore the importance of OGTT in identifying high-risk populations.

4.3. Plaque Burden in Prediabetes

To the best of our knowledge, this study is the first to demonstrate an association between IGT and adverse plaque characteristics using CCTA measurements. We found that IGT was associated with a higher burden of LAP. Supporting our findings, Gurudevan et al. [24] reported that both IFG and T2DM were associated with higher plaque burdens compared with NGT, and they found no significant differences between IFG and T2DM. However, unlike Gurudevan et al., our study focused specifically on IGT, which has been shown to have a stronger association with cardiovascular disease risk [25]. Similarly, Kuhirara et al. [26] used angioscopy in patients with known CAD and found that plaque vulnerability was more advanced in patients with prediabetes compared with patients with NGT. They also observed similar findings among those with prediabetes and T2DM. However, direct comparisons are limited by the difference in the definition of prediabetes, as Kuhirara et al. used FPG and HbA1c levels. Furthermore, they assessed plaque vulnerability by angioscopy.
Sassa et al. [27] observed similar levels of soft plaque characteristics and remodeling indexes in patients with IGT and T2DM, but they did not include an NGT group for comparison, which limits the direct comparability to our study. A previous study from our group [28] demonstrated an association between insulin resistance, measured by HOMA-IR, and necrotic plaque volume. However, we did not find a significant link between prediabetes, defined by OGTT, and necrotic core volume. Notably, we did not differentiate between IFG and IGT. In contrast to our current findings, the Paradigm Study [29] and Prospect Study [30] reported limited associations between prediabetes and plaque burden or progression, particularly over short follow-up periods. These findings may reflect the need for longer-term studies to capture the cumulative effects of prediabetes on plaque development. Additionally, the use of imaging modalities such as intravascular ultrasound in the Prospect Study may limit comparability with our findings.

4.4. High-Risk Plaque Features in Prediabetes

Quantitative plaque characteristics, such as plaque burden, are associated with the qualitative assessment of HRP features [31]. In our study, the NRS was more frequent in patients with IGT compared with NGT, while no significant differences were observed for positive remodeling and spotty calcifications. These findings are consistent with a study [32] that used OCT in patients undergoing percutaneous coronary intervention. The study showed that patients with IGT exhibited more vulnerable non-culprit lesions, characterized by a larger lipid core and a thinner fibrous cap, compared with patients with NGT. These characteristics were similar to those observed in patients with T2DM. However, that study consisted of a high-risk population undergoing intervention, whereas our study included low-risk patients with suspected stable CAD.
Interestingly, the Miami Heart Study [33], which included a large population of over 2300 asymptomatic adults without known CAD, found that worsening glycemic status, as measured by HbA1c, was associated with a higher prevalence of HRP features. Specifically, patients with prediabetes had an odds ratio of 1.7 for HRP features, while those with T2DM had an odds ratio of 2.5, compared with NGT. Our study population lies somewhere between these two cohorts, bridging the gap between high-risk intervention patients and low-risk asymptomatic individuals.

4.5. Methodological Considerations

A limitation lies in the cross-sectional nature of the study, which limits the ability to establish causal relationships between glycemic tolerance and plaque characteristics. Additionally, there was a delay between CCTA and blood sampling, which could potentially introduce variability. The OGTT was based on a single measurement, and while OGTT is widely used, the reproducibility for the 2h plasma glucose value has been questioned with the report of an intrapersonal coefficient of variation of 16.7% [34]. This variability could influence the classification of glycemic tolerance in some individuals. Plaque measurements were performed using validated semi-automatic methods with manual corrections when needed, which might introduce errors. Finally, the sample size and selection criteria, focusing on a specific subset of patients (only those with LAP lesions), may limit the generalizability of the findings to broader populations.

5. Conclusions

In patients with suspected stable coronary artery disease who exhibited coronary low-attenuation plaque lesions, those with impaired glucose tolerance had a higher low-attenuation burden and a greater frequency of napkin-ring signs compared with patients with normal glucose tolerance. These findings may provide insight into why prediabetes is frequently observed in patients with acute myocardial infarction. However, further research is needed to explore the underlying mechanisms and potential clinical implications of these associations, particularly regarding their role in predicting cardiovascular events.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcdd12020037/s1, Table S1. Patient characteristics according to glycemic tolerance; Table S2. Plaque burden and High-risk plaque characteristics according to glycemic tolerance.

Author Contributions

Conceptualization, T.R.A. and K.E.; data curation, T.R.A.; formal analysis, T.R.A. and R.A.M.; funding acquisition, T.R.A.; investigation, T.R.A.; methodology, T.R.A., L.J.H. and K.E.; project administration, T.R.A. and K.E.; software, T.R.A., K.S.O., L.J.H. and H.P.; supervision, J.L., S.A. and K.E.; validation, T.R.A. and K.S.O.; visualization, T.R.A.; writing—original draft, T.R.A., L.J.H. and K.S.O.; writing—review and editing, T.R.A., R.A.M., K.S.O., F.S.M., H.P., J.L., S.A., L.J.H. and K.E. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from the Region of Southern Denmark (Region Syd-349 danmarks Ph.d.-pulje) (grant number: 697).

Institutional Review Board Statement

Regional Committees on Health Research Ethics for Southern Denmark (ID S-20170094), as well as the Danish Data Protection Agency (ID 18/5857).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

The authors thank the student team working on the project, who helped collect the data, and the clinical biochemical department for their collaboration in data collection. We also express our gratitude to the Region of Southern Denmark for their financial support.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Norhammar, A.; Tenerz, A.; Nilsson, G.; Hamsten, A.; Efendíc, S.; Rydén, L.; Malmberg, K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet 2002, 359, 2140–2144. [Google Scholar] [CrossRef]
  2. Ferrannini, G.; De Bacquer, D.; De Backer, G.; Kotseva, K.; Mellbin, L.; Wood, D.; Rydén, L. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care 2020, 43, 726–733. [Google Scholar] [CrossRef] [PubMed]
  3. Ferrannini, G.; Tuomilehto, J.; De Backer, G.; Kotseva, K.; Mellbin, L.; Schnell, O.; Wood, D.; De Bacquer, D.; Rydén, L. Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: Experiences from the EUROASPIRE IV and V cohort studies. Lancet Diabetes Endocrinol. 2024, 12, 790–798. [Google Scholar] [CrossRef] [PubMed]
  4. Chen, F.; He, Y.; Wang, J.; Yu, L.; Gong, Q.; Chen, Y.; An, Y.; He, S.; Li, G.; Zhang, B. Influence of impaired glucose tolerance alone and combined with metabolic syndrome on long-term risk of cardiovascular events and mortality. J. Diabetes 2024, 16, e13598. [Google Scholar] [CrossRef]
  5. Suzuki, K.; Takano, H.; Kubota, Y.; Inui, K.; Nakamura, S.; Tokita, Y.; Kato, K.; Asai, K.; Shimizu, W. Plaque Characteristics in Coronary Artery Disease Patients with Impaired Glucose Tolerance. PLoS ONE 2016, 11, e0167645. [Google Scholar] [CrossRef] [PubMed]
  6. Yamamoto, H.; Kitagawa, T.; Ohashi, N.; Utsunomiya, H.; Kunita, E.; Oka, T.; Urabe, Y.; Tsushima, H.; Awai, K.; Kihara, Y. Noncalcified atherosclerotic lesions with vulnerable characteristics detected by coronary CT angiography and future coronary events. J. Cardiovasc. Comput. Tomogr. 2013, 7, 192–199. [Google Scholar]
  7. Thomsen, C.; Abdulla, J. Characteristics of high-risk coronary plaques identified by computed tomographic angiography and associated prognosis: A systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Imaging 2016, 17, 120–129. [Google Scholar] [PubMed]
  8. Motoyama, S.; Sarai, M.; Narula, J.; Ozaki, Y. Coronary CT angiography and high-risk plaque morphology. Cardiovasc. Interv. Ther. 2013, 28, 1–8. [Google Scholar] [CrossRef]
  9. Bittner, D.O.; Mayrhofer, T.; Puchner, S.B.; Lu, M.T.; Maurovich-Horvat, P.; Ghemigian, K.; Kitslaar, P.H.; Broersen, A.; Bamberg, F.; Truong, Q.A.; et al. Coronary Computed Tomography Angiography–Specific Definitions of High-Risk Plaque Features Improve Detection of Acute Coronary Syndrome. Circ. Cardiovasc. Imaging 2018, 11, e007657. [Google Scholar] [CrossRef] [PubMed]
  10. Ferencik, M.; Mayrhofer, T.; Bittner, D.O.; Emami, H.; Puchner, S.B.; Lu, M.T.; Meyersohn, N.M.; Ivanov, A.V.; Adami, E.C.; Patel, M.R.; et al. Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial. JAMA Cardiol. 2018, 3, 144–152. [Google Scholar] [CrossRef] [PubMed]
  11. Puchner, S.B.; Liu, T.; Mayrhofer, T.; Truong, Q.A.; Lee, H.; Fleg, J.L.; Nagurney, J.T.; Udelson, J.E.; Hoffmann, U.; Ferencik, M. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: Results from the ROMICAT-II trial. J. Am. Coll. Cardiol. 2014, 64, 684–692. [Google Scholar] [CrossRef]
  12. Nerlekar, N.; Ha, F.J.; Cheshire, C.; Rashid, H.; Cameron, J.D.; Wong, D.T.; Seneviratne, S.; Brown, A.J. Computed Tomographic Coronary Angiography–Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events. Circ. Cardiovasc. Imaging 2018, 11, e006973. [Google Scholar] [CrossRef] [PubMed]
  13. Nakazato, R.; Otake, H.; Konishi, A.; Iwasaki, M.; Koo, B.K.; Fukuya, H.; Shinke, T.; Hirata, K.; Leipsic, J.; Berman, D.S.; et al. Atherosclerotic plaque characterization by CT angiography for identification of high-risk coronary artery lesions: A comparison to optical coherence tomography. Eur. Heart J. Cardiovasc. Imaging 2015, 16, 373–379. [Google Scholar] [CrossRef] [PubMed]
  14. Takagi, H.; Leipsic, J.A.; Indraratna, P.; Gulsin, G.; Khasanova, E.; Tzimas, G.; Lin, F.Y.; Shaw, L.J.; Lee, S.E.; Andreini, D.; et al. Association of Tube Voltage With Plaque Composition on Coronary CT Angiography: Results From PARADIGM Registry. JACC Cardiovasc. Imaging 2021, 14, 2429–2440. [Google Scholar] [CrossRef] [PubMed]
  15. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020, 43 (Suppl. S1), S14–S31. [Google Scholar] [CrossRef]
  16. Anand, S.S.; Dagenais, G.R.; Mohan, V.; Diaz, R.; Probstfield, J.; Freeman, R.; Shaw, J.; Lanas, F.; Avezum, A.; Budaj, A.; et al. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: The EpiDREAM cohort study. Eur. J. Prev. Cardiol. 2012, 19, 755–764. [Google Scholar] [CrossRef]
  17. Williams, M.C.; Kwiecinski, J.; Doris, M.; McElhinney, P.; D’Souza, M.S.; Cadet, S.; Adamson, P.D.; Moss, A.J.; Alam, S.; Hunter, A.; et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation 2020, 141, 1452–1462. [Google Scholar] [CrossRef] [PubMed]
  18. Agatston, A.S.; Janowitz, W.R.; Hildner, F.J.; Zusmer, N.R.; Viamonte, M., Jr.; Detrano, R. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 1990, 15, 827–832. [Google Scholar] [CrossRef]
  19. Conte, E.; Annoni, A.; Pontone, G.; Mushtaq, S.; Guglielmo, M.; Baggiano, A.; Volpato, V.; Agalbato, C.; Bonomi, A.; Veglia, F.; et al. Evaluation of coronary plaque characteristics with coronary computed tomography angiography in patients with non-obstructive coronary artery disease: A long-term follow-up study. Eur. Heart J. Cardiovasc. Imaging 2016, 18, 1170–1178. [Google Scholar] [CrossRef] [PubMed]
  20. Yahyavi, S.K.; Snorgaard, O.; Knop, F.K.; Schou, M.; Lee, C.; Selmer, C.; Gislason, G.; Torp-Pedersen, C.; Blomberg Jensen, M.; Nissen Bonde, A. Prediabetes Defined by First Measured HbA(1c) Predicts Higher Cardiovascular Risk Compared With HbA(1c) in the Diabetes Range: A Cohort Study of Nationwide Registries. Diabetes Care 2021, 44, 2767–2774. [Google Scholar] [CrossRef] [PubMed]
  21. Marx, N.; Federici, M.; Schütt, K.; Müller-Wieland, D.; Ajjan, R.A.; Antunes, M.J.; Christodorescu, R.M.; Crawford, C.; Di Angelantonio, E.; Eliasson, B.; et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 2023, 44, 4043–4140. [Google Scholar]
  22. Marx, N.; Rydén, L.; Federici, M.; Marx-Schütt, K.; Verket, M.; Müller-Wieland, D.; Gerstein, H.C.; Chan, J.; Cosentino, F.; Holman, R.R.; et al. Great debate: Pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction. Eur. Heart J. 2024, 45, 5117–5126. [Google Scholar] [CrossRef] [PubMed]
  23. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354, 617–621.
  24. Gurudevan, S.; Garg, P.; Malik, S.; Khattar, R.; Saremi, F.; Hecht, H.; DeMaria, A.; Narula, J. Impaired fasting glucose is associated with increased severity of subclinical coronary artery disease compared to patients with diabetes and normal fasting glucose: Evaluation by coronary computed tomographic angiography. BMJ Open 2016, 6, e005148. [Google Scholar] [CrossRef] [PubMed]
  25. Qiao, Q.; Pyörälä, K.; Pyörälä, M.; Nissinen, A.; Lindström, J.; Tilvis, R.; Tuomilehto, J. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur. Heart J. 2002, 23, 1267–1275. [Google Scholar] [CrossRef] [PubMed]
  26. Kurihara, O.; Takano, M.; Yamamoto, M.; Shirakabe, A.; Kimata, N.; Inami, T.; Kobayashi, N.; Munakata, R.; Murakami, D.; Inami, S.; et al. Impact of prediabetic status on coronary atherosclerosis: A multivessel angioscopic study. Diabetes Care 2013, 36, 729–733. [Google Scholar] [CrossRef] [PubMed]
  27. Sassa, S.; Shimada, K.; Yoshida, K.; Tanaka, H.; Jissho, S.; Yoshikawa, J. Comparison of 64-slice multi-detector computed tomography coronary angiography between asymptomatic, type 2 diabetes mellitus and impaired glucose tolerance patients. J. Cardiol. 2008, 52, 133–139. [Google Scholar] [CrossRef] [PubMed]
  28. Larsson, J.; Auscher, S.; Shamoun, A.; Pararajasingam, G.; Heinsen, L.J.; Andersen, T.R.; Lindholt, J.S.; Diederichsen, A.C.P.; Lambrechtsen, J.; Egstrup, K. Insulin resistance is associated with high-risk coronary artery plaque composition in asymptomatic men between 65 and 75 years and no diabetes: A DANCAVAS cross-sectional sub-study. Atherosclerosis 2023, 385, 117328. [Google Scholar] [CrossRef] [PubMed]
  29. Neglia, D.; Caselli, C.; Maffei, E.; Cademartiri, F.; Meloni, A.; Bossone, E.; Saba, L.; Lee, S.E.; Sung, J.M.; Andreini, D.; et al. Rapid Plaque Progression Is Independently Associated With Hyperglycemia and Low HDL Cholesterol in Patients With Stable Coronary Artery Disease: A PARADIGM Study. Cardiovasc. Imaging 2024, 17, e016481. [Google Scholar] [CrossRef]
  30. Farhan, S.; Redfors, B.; Maehara, A.; McAndrew, T.; Ben-Yehuda, O.; De Bruyne, B.; Mehran, R.; Giustino, G.; Kirtane, A.J.; Serruys, P.W.; et al. Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical Outcome in Patients With Acute Coronary Syndromes: An Analysis From the PROSPECT Study. JACC Cardiovasc. Imaging 2019, 12, 733–741. [Google Scholar] [CrossRef] [PubMed]
  31. Liu, T.; Maurovich-Horvat, P.; Mayrhofer, T.; Puchner, S.B.; Lu, M.T.; Ghemigian, K.; Kitslaar, P.H.; Broersen, A.; Pursnani, A.; Hoffmann, U.; et al. Quantitative coronary plaque analysis predicts high-risk plaque morphology on coronary computed tomography angiography: Results from the ROMICAT II trial. Int. J. Cardiovasc. Imaging 2018, 34, 311–319. [Google Scholar] [CrossRef] [PubMed]
  32. Zhou, J.; Sheng, Z.; Liu, C.; Zhou, P.; Li, J.; Chen, R.; Song, L.; Zhao, H.; Yan, H. Association between Admission Hyperglycemia and Culprit Lesion Characteristics in Nondiabetic Patients with Acute Myocardial Infarction: An Intravascular Optical Coherence Tomography Study. J. Diabetes Res. 2020, 2020, 1763567. [Google Scholar] [CrossRef]
  33. Patel, K.V.; Budoff, M.J.; Valero-Elizondo, J.; Lahan, S.; Ali, S.S.; Taha, M.B.; Blaha, M.J.; Blankstein, R.; Shapiro, M.D.; Pandey, A.; et al. Coronary Atherosclerosis Across the Glycemic Spectrum Among Asymptomatic Adults: The Miami Heart Study at Baptist Health South Florida. Circ. Cardiovasc. Imaging 2023, 16, e015314. [Google Scholar] [CrossRef] [PubMed]
  34. Selvin, E.; Crainiceanu, C.M.; Brancati, F.L.; Coresh, J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch. Intern. Med. 2007, 167, 1545–1551. [Google Scholar] [CrossRef]
Jcdd 12 00037 g001
Figure 1. CONSORT flowchart. This flowchart illustrates the process of study sample selection, detailing patient eligibility based on exclusion criteria for CCTA scan analysis, glucose tolerance, and the presence of low-attenuation plaque lesions. CCTA = coronary CT angiography, n = number, T2DM = Type 2 Diabetes Mellitus, IFG = impaired fasting glucose, NGT = normal glucose tolerance, IGT = impaired glucose tolerance, LAP = low-attenuation plaque.
Figure 1. CONSORT flowchart. This flowchart illustrates the process of study sample selection, detailing patient eligibility based on exclusion criteria for CCTA scan analysis, glucose tolerance, and the presence of low-attenuation plaque lesions. CCTA = coronary CT angiography, n = number, T2DM = Type 2 Diabetes Mellitus, IFG = impaired fasting glucose, NGT = normal glucose tolerance, IGT = impaired glucose tolerance, LAP = low-attenuation plaque.
Jcdd 12 00037 g001
Jcdd 12 00037 g002
Figure 2. High-risk plaque features. This figure displays examples of high-risk plaque features: (A) Napkin-ring sign, (B) spotty calcification, (C) positive remodeling index. Images are derived from patient cases using QAngioCT Research Edition version 3.2.0.13 (Medis Medical Imaging) and include cross-sectional views for (A) and (B) and a longitudinal view for (C).
Figure 2. High-risk plaque features. This figure displays examples of high-risk plaque features: (A) Napkin-ring sign, (B) spotty calcification, (C) positive remodeling index. Images are derived from patient cases using QAngioCT Research Edition version 3.2.0.13 (Medis Medical Imaging) and include cross-sectional views for (A) and (B) and a longitudinal view for (C).
Jcdd 12 00037 g002
Jcdd 12 00037 g003
Figure 3. Shows the prevalence of low-attenuation plaque (LAP) lesions in the initial cohort of NGT and IGT patients (same abbreviations as in Figure 1).
Figure 3. Shows the prevalence of low-attenuation plaque (LAP) lesions in the initial cohort of NGT and IGT patients (same abbreviations as in Figure 1).
Jcdd 12 00037 g003
Jcdd 12 00037 g004
Figure 4. Low-attenuation plaque burden according to glycemic tolerance. This violin plot depicts the distribution of low-attenuation plaque burden (measured as a percentage of total plaque volume) in patients with impaired glucose tolerance (IGT, shown in blue) and normal glucose tolerance (NGT, shown in red). The width of each violin represents the density of patients with corresponding plaque burden values, highlighting the variation and overlap between the two groups.
Figure 4. Low-attenuation plaque burden according to glycemic tolerance. This violin plot depicts the distribution of low-attenuation plaque burden (measured as a percentage of total plaque volume) in patients with impaired glucose tolerance (IGT, shown in blue) and normal glucose tolerance (NGT, shown in red). The width of each violin represents the density of patients with corresponding plaque burden values, highlighting the variation and overlap between the two groups.
Jcdd 12 00037 g004
Table 1. Patient characteristics according to glycemic tolerance.
Table 1. Patient characteristics according to glycemic tolerance.
NGT
n = 93		IGT
n = 55		p-Value
Age, years, n (SD)64.7 (8.8)61.0 (9.4)0.02
Sex, male, n (%)62 (67%)42 (76%)0.2
BMI, kg/m2 (SD)27.4 (6.0)28.9 (4.3)0.1
Systolic BP, mmHg (SD)144 (25)150 (22)0.2
Diastolic BP, mmHg (SD)80 (13)83 (12)0.2
Never smoker, n (%)44 (47%)20 (36%)0.7
Former smoker, n (%)38 (41%)25 (45%)0.1
Active smoker, n (%)11 (12%)9 (16%)0.4
Family history of CVD, n (%)29 (31%)22 (40%)0.3
Fasting glucose, mmol/L (SD)5.6 (0.3)6.1 (0.5)<0.001
120 min glucose, mmol/L (SD)5.7 (1.1)8.7 (1.2)<0.001
HbA1c, mmol/mol (SD)35 (4)37 (3)0.03
Pre-diabetic HbA1c, n (%)34 (37%)18 (33%)0.7
Total cholesterol, mmol/L (SD)5.0 (1.1)4.6 (1.2)0.06
HDL, mmol/L (SD)1.5 (0.4)1.3 (0.3)<0.001
LDL, mmol/L (SD)2.9 (1.0)2.6 (1.1)0.2
Triglycerides, mmol/L (SD)1.3 (0.8)1.8 (0.9)0.003
CRP, mg/L (SD)2.1 (1.9)3.1 (2.8)0.02
Antihypertensive medication, n (%)49 (53%)32 (60%)0.2
Statins, n (%)26 (28%)26 (47%)0.02
Medical history
AMI2 (2%)2(4%)0.6
PCI or CABG1 (1%)1 (2%)0.7
Stroke3 (3%)2(4%)0.8
Heart failure1(1%)00.6
Total CACS, (IQR)73 (4–233)76 (1–214)0.5
Inflammatory disease6(6%)4(7%)0.8
LAP lesions:
NCP, n (%)36 (30%)30 (38%)0.2
Mixed mostly fibrous, n (%)72 (59%)42 (53%)0.4
Mixed mostly calcified, n (%)12 (10%)8 (10%)0.4
Data are presented as mean ± standard deviation (SD), median + interquartile range (IQR), or counts (n) + proportions (%). BMI = body mass index, BP = blood pressure, CVD = cardiovascular Disease, HbA1c = glycated Hemoglobin A1c, HDL = high-Density Lipoprotein, LDL = low-density lipoprotein, CRP = C-Reactive Protein, CACS = coronary artery calcium score, LAP = low-attenuation plaque, NCP = non-calcified plaque.
Table 2. High-risk plaque characteristics according to glycemic tolerance.
Table 2. High-risk plaque characteristics according to glycemic tolerance.
NGT
n = 122		IGT
n = 80		p-Value
Plaque location
Left anterior descending artery70 (57%)42 (53%)-
Circumflex artery18 (15%)5 (6%)-
Right coronary artery34 (28%)33 (41%)-
Plaque metrics
Lesion length, mm 17.5 (5.4)17.4 (5.8)0.9
TAV, mm3155.6 (72.9)157.5 (76.0)0.9
Degree stenosis %31%(18, 59)37(16, 62%)0.3
Plaque volumes, mm3
Calcified25.7 (37.7)22.1 (27.5)0.5
Non-calcified 109.8 (48.2)114.3 (61.4)0.6
Low-attenuation 12.6 (9.7)16.5 (12.5)0.01
Plaque burdens, %
Calcified 14.2 (14.2)12.8 (11.8)0.5
Non-calcified 72.3 (12.8)73.1 (10.5)0.7
Low-attenuation 8.623 (5.9)10.8 (6.8)0.02
HRP features, n (%)
Positive remodeling21 (17%)15 (19%)0.8
Spotty calcification28 (23%)26 (32%)0.1
Napkin-ring sign5 (5%)10 (12%)0.02
HRP ≥ 246 (38%)39 (49%)0.1
HRP ≥ 38 (7%)10 (13%)0.1
Data are presented as means ± SD or total count and percentage. HRP ≥ 2/3 refers to lesions where two or three high-risk plaque features are present. TAV = total atheroma volume, HRP = high-risk plaque.
Table 3. Linear and logistic regression models for high-risk plaque characteristics according to glycemic tolerance.
Table 3. Linear and logistic regression models for high-risk plaque characteristics according to glycemic tolerance.
NGT vs. IGTp-ValueNGT vs. IGTp-Value
UnivariateMultivariate
β β
Plaque volumes, mm3
Calcified 0.30.080.020.1
Non-calcified 4.40.50.040.6
Low-attenuation3.70.022.90.06
Plaque burdens, %
Calcified −0.10.70.30.3
Non-calcified 0.80.70.30.9
Low-attenuation0.40.020.30.03
HRP features, nOR OR
Positive remodeling1.10.81.040.9
Spotty calcifications1.60.11.40.4
Napkin-ring sign2.70.022.20.04
The multivariate analysis was adjusted for age, male sex, BMI, CRP, LDL, statin use, and smoking. HRP = high-risk plaque.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Andersen, T.R.; Overgaard, K.S.; Heinsen, L.J.; Mohamed, R.A.; Madsen, F.S.; Precht, H.; Lambrechtsen, J.; Auscher, S.; Egstrup, K. High-Risk Plaque Characteristics in Patients with Suspected Stable Coronary Artery Disease and Impaired Glucose Tolerance: A Coronary Computed Tomography Angiography Study. J. Cardiovasc. Dev. Dis. 2025, 12, 37. https://doi.org/10.3390/jcdd12020037

AMA Style

Andersen TR, Overgaard KS, Heinsen LJ, Mohamed RA, Madsen FS, Precht H, Lambrechtsen J, Auscher S, Egstrup K. High-Risk Plaque Characteristics in Patients with Suspected Stable Coronary Artery Disease and Impaired Glucose Tolerance: A Coronary Computed Tomography Angiography Study. Journal of Cardiovascular Development and Disease. 2025; 12(2):37. https://doi.org/10.3390/jcdd12020037

Chicago/Turabian Style

Andersen, Thomas Rueskov, Katrine Schultz Overgaard, Laurits Juhl Heinsen, Roda Abdulkadir Mohamed, Freja Sønder Madsen, Helle Precht, Jess Lambrechtsen, Søren Auscher, and Kenneth Egstrup. 2025. "High-Risk Plaque Characteristics in Patients with Suspected Stable Coronary Artery Disease and Impaired Glucose Tolerance: A Coronary Computed Tomography Angiography Study" Journal of Cardiovascular Development and Disease 12, no. 2: 37. https://doi.org/10.3390/jcdd12020037

APA Style

Andersen, T. R., Overgaard, K. S., Heinsen, L. J., Mohamed, R. A., Madsen, F. S., Precht, H., Lambrechtsen, J., Auscher, S., & Egstrup, K. (2025). High-Risk Plaque Characteristics in Patients with Suspected Stable Coronary Artery Disease and Impaired Glucose Tolerance: A Coronary Computed Tomography Angiography Study. Journal of Cardiovascular Development and Disease, 12(2), 37. https://doi.org/10.3390/jcdd12020037

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop